Purpose. The use of coagulation factor VIIa (recombinant) for the treatment of warfarin-induced intracranial hemorrhage (ICH) is described. Summary. ICH is a devastating disorder that can be exacerbated by the use of oral anticoagulation. The treatment of warfarinassociated ICH involves the prompt reversal of anticoagulation to allow for surgical procedures, if necessary. Despite limited labeled indications, factor VIIa (recombinant) has been used to reverse warfarininduced anticoagulation in patients with active hemorrhage, partly due to the rapid effect of factor VIIa on the International Normalized Ratio and the ability to administer the drug quickly in acute settings. The efficacy of factor VIIa (recombinant) for the reversal of anticoagulation in patients with warfarin-associated ICH has been described in several case reports, case series, and retrospective cohort studies. Based on these reports, the use of factor VIIa (recombinant) for the treatment of warfarinassociated ICH may be a viable alternative or adjunct therapy to standard treatment with fresh-frozen plasma and vitamin K. However, due to the nature of these reports, future controlled trials should be conducted to verify the exact place for factor VIIa (recombinant) for this indication. Thromboembolic complications are rare but serious complications secondary to the use of factor VIIa (recombinant). Though differences exist in the reported rate of thromboembolic complications associated with factor VIIa (recombinant), factor VIIa (recombinant) should be used with caution in patients with a predisposition to thromboembolic complications. Conclusion. Use of factor VIIa (recombinant) may be considered for reversal of anticoagulation in patients with warfarinassociated ICH. However, patients should be screened for increased risk of thrombosis before administration of the drug.

This article presents information on the blood coagulation factor VIIa. Factor VIIa is a preparation of recombinant human antihaemophilic factor VII. It acts as a drug to reduce or stop bleeding and is used to treat disorders in which bleeding is prolonged and potentially dangerous, usually...

Editorial. Focuses on the lethal outcome of the use of prothrombin complex preparations for treatment of bleeding. Overview of clotting factor transfusion; Consequences of prothrombin complex infusion; Recommendations.

An encyclopedia entry for "factor VIII" is presented. It refers to one of the blood proteins involved in blood clotting. A reduction in the level of factor VIII in the blood would lead to the condition called haemophilia where there is a tendency to abnormal bleeding and to prolonged bleeding...